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Abstract
Background: Chronic progressive external ophthalmoplegia (CPEO) is a classical mitochondrial ocular disorder characterised
by bilateral progressive ptosis and ophthalmoplegia. These ocular features can develop either in isolation or in association
with other prominent neurological deficits (CPEO+). Molecularly, CPEO can be classified into two distinct genetic subgroups
depending on whether patients harbour single, large-scale mitochondrial DNA (mtDNA) deletions or multiple mtDNA
deletions secondary to a nuclear mutation disrupting mtDNA replication or repair. The aim of this magnetic resonance
imaging (MRI) study was to investigate whether the ophthalmoplegia in CPEO is primarily myopathic in origin or whether
there is evidence of contributory supranuclear pathway dysfunction.
Methods: Ten age-matched normal controls and twenty patients with CPEO were recruited nine patients with single, large-
scale mtDNA deletions and eleven patients with multiple mtDNA deletions secondary to mutations in POLG, PEO1, OPA1,
and RRM2B. All subjects underwent a standardised brain and orbital MRI protocol, together with proton magnetic resonance
spectroscopy in two voxels located within the parietal white matter and the brainstem.
Results: There was evidence of significant extraocular muscle atrophy in patients with single or multiple mtDNA deletions
compared with controls. There was no significant difference in metabolite concentrations between the patient and control
groups in both the parietal white matter and brainstem voxels. Volumetric brain measurements revealed marked cortical
and cerebellar atrophy among patients with CPEO+ phenotypes.
Conclusion: The results of this study support a primary myopathic aetiology for the progressive limitation of eye
movements that develops in CPEO.
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Introduction
Chronic progressive external ophthalmoplegia (CPEO) is a
slowly progressive extraocular muscle disorder characterised by
bilateral, usually symmetrical, limitation of eye movements and
ptosis [1]. This classical manifestation of mitochondrial diseases
can develop either in isolation or in association with other
disabling neurological features, referred to as CPEO+ [2,3].
Unsurprisingly, CPEO results in significant morbidity with a
marked negative impact on the patient’s quality of life [4].
Molecularly, CPEO can be classified into two distinct genetic
subgroups depending on whether patients harbour single, large-
scale mitochondrial DNA (mtDNA) deletions or multiple mtDNA
deletions secondary to a nuclear mutation disrupting mtDNA
replication or repair [5,6].
The aim of this magnetic resonance imaging (MRI) study was to
investigate whether the limitation of eye movements in CPEO is
myopathic in origin or whether there is evidence of contributory
brainstem dysfunction with magnetic resonance spectroscopy
(MRS). Brain volumetric measurements were also performed to
assess the extent of central nervous system involvement and
whether this correlated with the development of extraocular
neurological features in patients with CPEO+ phenotypes.
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Patients and Methods
Study Cohort
The study cohort included: (i) nine patients with single,
large-scale mtDNA deletions (six females and three males,
mean age = 50.8 years, standard deviation (SD) = 3.0 years), (ii)
eleven patients with multiple mtDNA deletions (four females,
seven males, mean age = 51.6 years, SD=2.8 years), and (iii)
ten age-matched normal controls (seven females and three
males, mean age 50.3, SD=2.3 years) (Table 1). Recruitment
was limited to patients younger than 70 years of age to exclude
possible age-related confounding factors, and to those with
disease duration of more than five years. This study had the
relevant institutional ethical approval (County Durham & Tees
Valley 1 Research Ethics Committee, 08/H0905/106) and it
was carried out in compliance with the Declaration of Helsinki.
Participants provided their written consent for participation
into this study.
Clinical and Molecular Investigations
All patients were assessed by an experienced multi-disciplinary
team of neurologists and ophthalmologists to define the clinical
phenotype and disease severity (Table 1). The limitation of eye
movements was quantified from 21 to 24, with 21 indicating
only mild limitation and 24 being the worst score, the eye being
unable to move from the primary position of gaze [7]. Ptosis
severity was graded according to the height of the palpebral
aperture: (i) severe (,4 mm), (ii) moderate (4–6 mm), and (iii) mild
(.6 mm) [8]. Additional histochemical and molecular investiga-
tions were carried out on skeletal muscle biopsies to confirm the
clinical diagnosis of CPEO. A nuclear mutation was identified in
nine of the eleven patients with CPEO found to harbour multiple
mtDNA deletions: (i) POLG mutations (n = 4) [9], PEO1 mutations
(n = 3) [10], OPA1 mutations (n = 1) [11], and RRM2B mutations
(n = 1) [12]. For two patients, an underlying nuclear genetic defect
has so far not been identified. Both these patients had typical
clinical features of CPEO and mitochondrial histochemistry
performed on skeletal muscle biopsies showed high levels of
Figure 1. Extraocular muscle morphology in patients with CPEO and controls. Representative cross-sections of extraocular muscles have
been provided at three different anatomical locations. All four recti muscles in patients harbouring single, large-scale deletions or multiple DNA
deletions were atrophic compared with controls. Slice locations: I = 4 mm behind slice II towards the orbital apex; II = central slice; III = 4 mm in front
of slice II towards the extraocular muscle insertions onto the globe.
doi:10.1371/journal.pone.0075048.g001
Table 2. Extraocular muscle volumes in patients with CPEO and controls.
Genetic group Superior rectus Inferior rectus Medial rectus Lateral rectus
Mean ± SD (mm3) (%)a Mean ± SD (mm3) (%)a Mean ± SD (mm3) (%)a Mean ± SD (mm3) (%)a
Single mtDNA deletion
(n=9)
582.6641.8 (35.4%) 525.0630.6 (28.2%) 556.6617.9 (32.3%) 629.3625.9 (24.7%)
P,0.0001 P,0.0001 P,0.0001 P,0.0001
Multiple mtDNA deletions
(n=11)
547.3623.7 (39.4%) 523.1619.9 (28.5%) 491.8620.3 (40.2%) 589.1623.6 (29.5%)
P,0.0001 P,0.0001 P,0.0001 P,0.0001
Controls (n =10) 902.4635.9 731.5626.9 822.6630.1 835.3634.5
aPercentage reduction compared with controls. The respective P values indicate the level of significance for the comparisons with the control data set. SD: standard
deviation.
doi:10.1371/journal.pone.0075048.t002
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PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e75048
cytochrome c oxidase-deficient fibres in addition to prominent
ragged red fibres.
Magnetic Resonance Studies
MRI and MRS data were acquired on a 3-Tesla Philips Achieva
clinical MR system using an 8-channel head coil. Proton MRS
analysis was performed by an experienced research physicist (FES)
to derive brain metabolite concentrations in the parietal white
matter and brainstem regions: (i) choline; (ii) creatine; (iii) total
glutamate and glutamine (Glx); (iv) myo-inositol; and (v) N-acetyl-
aspartate (NAA). Extraocular and brain compartment volumes
were measured using standardised semi-automated segmentation
protocols (Text S1), with a high degree of intra- and inter-
observer reliability (Table S1).
Statistical Analysis
Statistical analysis was performed using GraphPadTM Prism v5
statistical software (San Diego, CA). Group comparisons were
made using the unpaired t-test. Intra-observer and inter-observer
variability for the measurement of extraocular muscle and brain
volumes was assessed with Pearson correlation coefficient (r).
Results
Extraocular Muscle Morphology
There was a significant reduction in extraocular muscle volumes
in the CPEO group compared with normal controls for all four
recti muscles (Figure 1), ranging from 24.7% to 40.2% (Table 2
and Figure 2). No significant difference in extraocular muscle
volumes was found between the two eyes from the same patient
(Table 3 and Figure 3). No specific MRI signal abnormalities
were identified along the course of the extraocular muscles in
patients with CPEO harbouring either single or multiple mtDNA
deletions.
Brain Metabolites and Compartment Volumes
There was no significant difference in metabolite concentrations
between the patient and control groups in both the parietal white
matter and brainstem voxels (Table 4). There was a statistically
significant reduction in total grey matter and cerebellar volumes
for both patients with single deletions and multiple mtDNA
deletions (Table 5). On subgroup analysis, the reduction in total
grey matter and cerebellar volumes was apparent for patients with
Figure 2. Comparison of extraocular muscle volumes between patients with CPEO and controls. Box plot of extraocular muscle volume
data with the whiskers representing the minimum and maximum volumes. The ends of the boxes are the upper and lower quartiles, the vertical
lengths of the boxes indicate the interquartile range, and the lines within the boxes represent the median volume for each group. CPEO cohort:
single = single mtDNA deletion; multiple =multiple mtDNA deletions.
doi:10.1371/journal.pone.0075048.g002
Table 3. Interocular comparison of extraocular muscle volumes in patients with CPEO.
Anatomical side Superior rectus Inferior rectus Medial rectus Lateral rectus
Mean ± SD (mm3) Mean ± SD (mm3) Mean ± SD (mm3) Mean ± SD (mm3)
Left eye (n =20) 556.4627.0 502.5626.8 514.0617.2 593.6624.6
Right eye (n =20) 569.9637.3 545.4621.6 527.9623.9 620.7625.2
P value 0.7707 0.2205 0.6374 0.4469
The P value for each rectus muscle indicates the level of significance for the comparison between the left and right eye. SD= standard deviation.
doi:10.1371/journal.pone.0075048.t003
Magnetic Resonance Studies in CPEO
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CPEO+, but not for those with pure CPEO phenotypes
(Figure 4).
Discussion
This study has shown clear evidence of significant extraocular
muscle atrophy involving all four recti muscles in CPEO. This
striking observation was noted for both patients with single, large-
scale mtDNA deletions and for those harbouring multiple mtDNA
deletions secondary to an underlying nuclear genetic defect. In a
previous report of nine patients with CPEO, Carlow and colleagues
observed a significant reduction in extraocular muscle volumes for
the inferior rectus, medial rectus and lateral rectus [13]. The
superior rectus was not assessed in their study and the diagnosis of
CPEO was made on clinical grounds, precluding any genetic
subgroup analysis. In a subsequent study, Ortube and colleagues
measured extraocular muscle volumes in five patients with a
clinical diagnosis of CPEO [14]. In contrast to the findings of our
study, a reduction in extraocular muscle volume was noted for the
superior rectus muscle only, but not for the other recti muscles
despite a severe degree of ophthalmoplegia. There were, however,
Figure 3. Interocular correlation of extraocular muscle volumes in patients with CPEO. r = Pearson correlation coefficient.
doi:10.1371/journal.pone.0075048.g003
Table 4. Metabolite concentrations in parietal white matter and brainstem regions.
Voxel location Subject group Choline Creatine Glx Myo-inositol NAA
Mean ± SD (mM) Mean ± SD (mM) Mean ± SD (mM) Mean ± SD (mM) Mean ± SD (mM)
Parietal white matter Single mtDNA
deletion (n=9)
1.560.1 10.061.4 28.961.8 2.860.7 15.461.0
P = 0.1970 P = 0.1428 P = 0.2636 P = 0.4628 P = 0.5933
Multiple mtDNA
deletions (n =11)
1.460.1 10.460.5 25.661.6 1.860.3 13.060.9
P = 0.7495 P = 0.0825 P = 0.0451 P = 0.1703 P = 0.0171
Controls (n =10) 1.360.3 12.562.7 32.862.9 4.462.1 16.060.7
Brainstem Single mtDNA
deletion (n=9)
1.560.1 10.760.6 28.062.0 4.160.6 11.160.5
P = 0.4266 P = 0.7425 P = 0.6837 P = 0.2336 P = 0.3711
Multiple mtDNA
deletions (n =11)
1.460.1 10.061.2 23.563.1 4.260.9 11.860.9
P = 0.3260 P = 0.5836 P = 0.4064 P = 0.2865 P = 0.8390
Controls (n =10) 1.760.6 11.062.5 26.762.2 5.961.3 12.160.8
The respective P values indicate the level of significance for the comparisons with the control data set, with P,0.0167 being the threshold level for statistical
significance after Bonferroni correction for multiple testing.
doi:10.1371/journal.pone.0075048.t004
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a number of limitations to the study by Ortube and colleagues,
including the relatively small number of patients that were
recruited and the lack of a confirmatory molecular diagnosis.
Furthermore, only a relatively small portion of the extraocular
muscle belly was sampled, which could have underestimated the
degree of atrophy in the recti muscles.
Our study is the first to demonstrate objectively that the extent
of extraocular muscle atrophy in CPEO is highly symmetrical
between the two eyes of the same patient, reflecting the
ophthalmoplegia pattern observed clinically [1]. No specific
MRI signal abnormalities were identified throughout the whole
length of the extraocular muscles in the twenty patients with
CPEO that were investigated. A number of other ocular motility
disorders can result in bilateral progressive ophthalmoplegia and
differentiating these from CPEO can sometimes be challenging,
especially when access to specialist mitochondrial genetic services
is not routinely available. Although future prospective studies are
needed to clarify this further, based on their characteristic
extraocular muscle differences, MRI evaluation of the orbit could
prove a useful adjunct in the diagnostic evaluation of this group of
patients.
A variable decrease in N-acetyl-aspartate (NAA) has previously
been reported in the brain of patients with the Kearns-Sayre
syndrome – a particularly severe clinical phenotype characterised
by the development of CPEO and pigmentary retinopathy before
the age of twenty years, often in association with progressive
cardiac conduction block [15,16]. There was no significant
difference in metabolite concentrations between the CPEO and
control groups in our study. These proton MRS findings are
consistent with the later onset and less severe neurological course
in the patients that were recruited, none of whom fulfilled the
criteria for the Kearns-Sayre syndrome.
Patients with CPEO+ features had significantly reduced total
grey matter and cerebellar volumes compared with controls, in
keeping with the higher burden of neurological disease in this
specific patient population. The prominent degree of atrophy seen
Table 5. Volumetric brain measurements in patients with CPEO harbouring single and multiple mtDNA deletions.
Genetic group Grey matter White matter Brainstem Cerebellum
Mean ± SD (cm3) (%)a Mean ± SD (cm3) (%)a Mean ± SD (cm3) (%)a Mean ± SD (cm3) (%)a
Single mtDNA deletion
(n=9)
594.269.6 (6.6%) 437.9614.2 (7.9%) 28.260.8 (7.2%) 112.663.9 (10.8%)
P = 0.0402 P = 0.1168 P = 0.0575 P = 0.0094
Multiple mtDNA deletions
(n=11)
572.3622.7 (10.1%) 462.8620.7 (2.6%) 28.161.1 (7.6%) 111.064.0 (12.1%)
P = 0.0344 P = 0.6516 P = 0.1012 P = 0.0061
Controls (n =10) 636.5615.8 475.3617.3 30.460.6 126.362.7
aPercentage reduction compared with controls. The respective P values indicate the level of significance for the comparisons with the control data set. SD = standard
deviation.
doi:10.1371/journal.pone.0075048.t005
Figure 4. Comparison of brain compartment volumes between patients with CPEO and controls.
doi:10.1371/journal.pone.0075048.g004
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in the cerebellum further highlights the particular vulnerability of
this specific brain region to the deleterious consequences of
mtDNA defects [17,18]. Patients with CPEO did not have
significantly reduced brainstem volumes compared with controls
and no brainstem metabolite abnormalities were detected with
proton MRS. These observations, taken in conjunction with the
marked atrophy of the extraocular muscles, support a primary
myopathic origin for the progressive ophthalmoplegia seen in
CPEO. However, some caution is required with regards to the
subgroup comparisons given the relatively small number of
patients in the single and multiple mtDNA deletion groups, and
the different nuclear genetic defects involved. Furthermore,
although CPEO is characterised by a significant myopathy
involving the extraocular muscles, the degree of atrophy
observed could still result, at least partly, from degeneration of
the oculomotor nuclei as has been observed in some patients
[19,20].
This comprehensive magnetic resonance study of patients with
molecularly confirmed CPEO has revealed a number of important
findings that are directly relevant to our understanding of the
underlying pathophysiology in this mitochondrial ocular disorder.
In addition to marked generalised extraocular muscle atrophy,
there was clear evidence of significant CNS involvement in this
disorder, which becomes clinically manifest in a subgroup of
patients.
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